ICMR transfers three Indigenous Medical Technologies to Industry at National Technology Day 2026

1. At a Glance

• On National Technology Day 2026 (11 May 2026), the Indian Council of Medical Research (ICMR) licensed three indigenously developed medical technologies to industry partners at the national programme 'विज्ञान–Tech' held at BRIC–National Institute of Immunology (NII), New Delhi [S1].
• The event embodies a "Whole-of-Government" approach, with 14 scientific ministries/departments coordinated by the Office of the Principal Scientific Adviser (PSA) and Department of Biotechnology (DBT) [S1].
• For UPSC, it links S&T policy (GS-III), health-sector self-reliance (Atmanirbhar Bharat in MedTech), and public R&D-to-industry technology transfer.

2. Why in the News

• 11 May 2026: ICMR transferred three medical technologies to industry at the विज्ञान–Tech programme on National Technology Day [S1].
• Follow-on event: ICMR's "Medical Innovations Patent Mitra: Innovators-to-Industry (I2I) Connect" in New Delhi later in 2026 transferred 41 technologies to industry — described as India's largest biomedical innovation/tech-transfer event [S2].

3. Background & Evolution

• National Technology Day observed annually on 11 May since 1999, commemorating Pokhran-II nuclear tests (1998) and the indigenous Hansa-3 aircraft / Trishul missile trials; declared by PM Atal Bihari Vajpayee [S1].
• ICMR, established 1911 (as Indian Research Fund Association; renamed ICMR in 1949), is the apex body for biomedical research under the Department of Health Research, Ministry of Health & Family Welfare [S1].
• ICMR's "Medical Innovations Patent Mitra" programme institutionalises licensing of publicly funded biomedical IP to Indian industry [S2].

4. Core Static Facts

• Event: विज्ञान–Tech, National Technology Day 2026 [S1].
• Date: 11 May 2026 [S1].
• Venue: BRIC–National Institute of Immunology (NII), New Delhi [S1].
• Coordinator: Office of the Principal Scientific Adviser (PSA) with DBT [S1].
• Participating bodies: 14 Scientific Ministries/Departments [S1].
• Chief guest/Inauguration: Union MoS (I/C) Science & Technology, Dr. Jitendra Singh [S1].
• ICMR exhibits: ~25 promising technologies across diagnostics, medical devices, digital health, disease surveillance, translational research [S1].
• Three transferred technologies (partial list confirmed):
• Affordable PSP-94 ELISA (for prostate biopsy decisions when PSA < 20 ng/ml) — developed by ICMR–National Institute for Research in Reproductive & Child Health / Women's Health (NIRWH) → licensed to KrishGen Labs [S1].
• Factor VIII Inhibitors / Coagulation Disorder Point-of-Care Diagnostic — developed by ICMR–National Institute for Research on Blood and Immune Disorders (NIRBID) → licensed to Merrill Life Sciences [S1].
• Third technology: additional ICMR diagnostic/device licensed under Patent Mitra (full name not in cited release) [S1].

5. Multi-Dimensional Analysis

Scientific / Technological - PSP-94 ELISA addresses false-positive PSA biopsies, reducing unnecessary prostate interventions — indigenous, affordable diagnostic substitute for imports [S1]. - Factor VIII inhibitor PoC diagnostic targets haemophilia management, a niche where Indian patients depend on costly foreign assays [S1].

Economic - Tech-transfer under Patent Mitra converts publicly funded IP into commercial MedTech, supporting Make-in-India / Atmanirbhar Bharat in medical devices (India's medical device market is ~80% import-dependent) [S2]. - Follow-on I2I Connect transferred 41 technologies, indicating scaling of ICMR's commercialization pipeline [S2].

Administrative / Governance - "Whole-of-Government" design under PSA bridges DBT, DST, MoHFW (DHR), MeitY, MoES etc.; reduces siloed S&T funding [S1].

Social - Affordable diagnostics for prostate cancer triage and bleeding disorders improve access for non-metro / lower-income patients [S1].

Strategic - Indigenous diagnostics reduce strategic dependence on imported reagents/kits — a vulnerability exposed during COVID-19 [S1].

6. Recent Developments (last 12–18 months)

• May 2026: ICMR transfers 3 technologies on National Technology Day at NII, Delhi [S1].
• 2026: ICMR's I2I Connect — Patent Mitra event transfers 41 biomedical technologies to industry [S2].
• ICMR continues showcase under "विज्ञान–Tech" — first edition convening 14 scientific departments together [S1].

7. Prelims Hooks

• National Technology Day: 11 May, commemorating Pokhran-II (1998) [S1].
• विज्ञान–Tech 2026 venue: BRIC–National Institute of Immunology, New Delhi [S1].
• Coordinating body: Office of the Principal Scientific Adviser (currently under Cabinet Secretariat), with DBT [S1].
• 14 scientific ministries/departments participated in विज्ञान–Tech 2026 [S1].
• ICMR functions under the Department of Health Research, Ministry of Health & Family Welfare — NOT under DST or DBT [S1].
• PSP-94 ELISA developed by ICMR-NIRWH, licensed to KrishGen Labs — used when PSA < 20 ng/ml [S1].
• Factor VIII Inhibitor PoC diagnostic developed by ICMR-NIRBID, licensed to Merrill Life Sciences [S1].
• ICMR's licensing framework: Medical Innovations Patent Mitra (Innovators-to-Industry / I2I Connect) [S2].
• Inaugurated by Dr. Jitendra Singh, MoS (I/C) Science & Technology [S1].
• BRIC = Biotechnology Research and Innovation Council, an autonomous society under DBT consolidating 14 DBT institutes [S1].
• I2I 2026 event transferred 41 technologies — India's largest biomedical tech-transfer event [S2].

8. Mains Relevance

• GS-III: Science & Technology — "Indigenization of technology and developing new technology"; "Achievements of Indians in S&T".
• GS-II: Government policies and interventions — health sector; "Issues relating to development and management of Social Sector/Health".
• Plausible question stems: 1. "Public R&D in India suffers from a 'lab-to-market' gap. Examine ICMR's Patent Mitra / I2I model as a corrective." 2. "Discuss the role of indigenous diagnostics in achieving health self-reliance under Atmanirbhar Bharat." 3. "Evaluate the 'Whole-of-Government' approach to scientific innovation as showcased in विज्ञान–Tech 2026."

9. Related Topics to Study Next

• PM-Ayushman Bharat Health Infrastructure Mission (PM-ABHIM) — health system capacity.
• National Medical Devices Policy 2023 — MedTech ecosystem framework.
• BIRAC & BRIC (DBT) — biotech translation bodies.
• Anusandhan National Research Foundation (ANRF) — funding architecture; ANRF–ICMR–Gates Maha MedTech Mission (2026) [S2].
• Pokhran-II (1998) & India's nuclear doctrine — historical anchor of NTD.
• Patents Act, 1970 & TRIPS flexibilities — IP transfer context.
• Production Linked Incentive (PLI) for Medical Devices.
• ICMR–NIV Pune / NIE Chennai — institutional knowledge for Prelims.

10. Common Errors / Trap Areas

• ICMR is under MoHFW (DHR), not DST/DBT — frequent MCQ trap.
• National Technology Day = 11 May, distinct from National Science Day (28 Feb, Raman Effect) and National Mathematics Day (22 Dec, Ramanujan).
• PSA is under the Cabinet Secretariat, not Ministry of Science & Technology.
• BRIC (umbrella of DBT institutes) ≠ "BRICS" grouping — same acronym, unrelated.
• Pokhran-II (1998) is the trigger; Pokhran-I (Smiling Buddha, 1974) is not commemorated on NTD.

11. Sources

• [S1] ICMR transfers three Indigenous Medical Technologies to Industry at National Technology Day 2026 — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2259926&reg=1&lang=1 — (tier 1)
• [S2] ICMR organizes India's largest biomedical innovation and technology transfer event "Medical Innovations Patent Mitra: I2I Connect" — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2264989 — (tier 1)
• [S3] ANRF, in collaboration with ICMR and Gates Foundation, launches Maha MedTech Mission — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2182432 — (tier 1)
• [S4] ICMR Licenses Nine Breakthrough Health Technologies to Industry Partners at India MedTech Expo 2025 — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2163759 — (tier 1)